Allo CD7 CAR WU-CART-007
Contact
Description
The purpose of this study is to determine thesafety and tolerability of an experimental form of therapy, known as WU-CART-007(“study drug”). WU-CART-007 uses immunecells, called T cells, that are genetically changed to identify cancer cells.In this study, T cells are collected from a healthy human donor and have beenmodified in a laboratory. If the genetically changed T cells recognize andattach to cancer cells, they may have the ability to kill those cancer cells.
Patients with T-cell Acute Lymphoblatic Leukemia (T-ALL) orLymphoblastic Lymphoma (LBL), where the disease has come back (relapsed) or hasnot responded to treatment (refractory) may be eligible for the study.
Eligibility and criteria
What to expect
As a participant in the research you will:
- Receive a study drug WU-CART-007
- Avoid taking certain medications (steroids,chemotherapy agents)
- Stay in the hospital for at least 7 days afterreceiving the study drug
- Complete follow up visits
- Have research blood samples drawn
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.